Document is current
Any future updates will be listed below
-
Authors
Zeidan, Amer M.
Bewersdorf, Jan Philipp https://orcid.org/0000-0003-3352-0902
Buckstein, Rena
Sekeres, Mikkael A. https://orcid.org/0000-0003-2009-6524
Steensma, David P.
Platzbecker, Uwe https://orcid.org/0000-0003-1863-3239
Loghavi, Sanam https://orcid.org/0000-0001-8980-3202
Boultwood, Jacqueline https://orcid.org/0000-0002-4330-2928
Bejar, Rafael https://orcid.org/0000-0002-5603-4598
Bennett, John M.
Borate, Uma
Brunner, Andrew M.
Carraway, Hetty https://orcid.org/0000-0001-5241-3614
Churpek, Jane E.
Daver, Naval G. https://orcid.org/0000-0001-7103-373X
Della Porta, Matteo
DeZern, Amy E.
Efficace, Fabio
Fenaux, Pierre
Figueroa, Maria E.
Greenberg, Peter
Griffiths, Elizabeth A. https://orcid.org/0000-0002-0288-8248
Halene, Stephanie https://orcid.org/0000-0002-2737-9810
Hasserjian, Robert P. https://orcid.org/0000-0002-7753-0697
Hourigan, Christopher S. https://orcid.org/0000-0002-6189-8067
Kim, Nina https://orcid.org/0000-0002-1809-0417
Kim, Tae Kon
Komrokji, Rami S. https://orcid.org/0000-0002-1876-5269
Kutchroo, Vijay
List, Alan F.
Little, Richard F. https://orcid.org/0000-0002-4091-1699
Majeti, Ravi https://orcid.org/0000-0002-5814-0984
Nazha, Aziz
Nimer, Stephen D. https://orcid.org/0000-0003-2439-7586
Odenike, Olatoyosi
Padron, Eric https://orcid.org/0000-0002-4707-7916
Patnaik, Mrinal M. https://orcid.org/0000-0001-6998-662X
Roboz, Gail J.
Sallman, David A. https://orcid.org/0000-0003-0504-8233
Sanz, Guillermo https://orcid.org/0000-0002-2767-8191
Stahl, Maximilian
Starczynowski, Daniel T. https://orcid.org/0000-0002-5771-7462
Taylor, Justin https://orcid.org/0000-0003-4407-6325
Xie, Zhuoer https://orcid.org/0000-0003-1266-9804
Xu, Mina https://orcid.org/0000-0001-9513-245X
Savona, Michael R. https://orcid.org/0000-0003-3763-5504
Wei, Andrew H.
Abdel-Wahab, Omar
Santini, Valeria https://orcid.org/0000-0002-5439-2172
-
Funding
Funding for this research was provided by:
Leukemia and Lymphoma Society
Leukemia and Lymphoma Society
American Cancer Society
- License Information
-
More Information
Article History
Received: 1 August 2022
Revised: 28 September 2022
Accepted: 4 October 2022
First Online: 20 October 2022
Competing interests
: The first international workshop on MDS (iwMDS) was planned by an independent scientific steering committee of the International Consortium for MDS (icMDS). The meeting was supported by unrestricted educational grants from Gilead, Novartis, BMS, Syros, Geron, and Karyopharm to Magdalen Medical/VJHemOnc. The participants met in Miami, FL in June 2022, and deliberated the content of this manuscript, which was subsequently finalized after the meeting. The meeting sponsors had no involvement in the development of this manuscript. AN, DPS, RB, AFL, CSH, and NK, and all other authors authored this manuscript in their personal capacity and their views do not necessarily represent/reflect that of their employers. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. MMP, EP, UP, RB, and SL were authors on WHO classification. RPH was co-chair of Pathology International Consensus Classification (ICC) and co-leader of ICC Pre-malignant Clonal Cytopenias and Myelodysplastic Syndromes working group. OO, MRS, and AHW were authors on the ICC classification. AMZ received research funding (institutional) from Celgene/BMS, Abbvie, Astex, Pfizer, Medimmune/AstraZeneca, Boehringer-Ingelheim, Cardiff oncology, Incyte, Takeda, Novartis, Aprea, and ADC Therapeutics. AMZ participated in advisory boards, and/or had a consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Celgene/BMS, Jazz, Incyte, Agios, Boehringer-Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Taiho, Seattle Genetics, BeyondSpring, Cardiff Oncology, Takeda, Ionis, Amgen, Janssen, Epizyme, Syndax, Gilead, Kura, Chiesi, ALX Oncology, BioCryst, Notable, Orum, and Tyme. AMZ served on clinical trial committees for Novartis, Abbvie, Gilead, BioCryst, Abbvie, ALX Oncology, Geron and Celgene/BMS. DPS is an employee of Novartis. Uwe Platzbecker received honoraria from BMS, Jazz Pharmaceuticals, Abbvie, Geron. The National Heart, Lung, and Blood Institute receives research funding for the laboratory of CSH from Sellas and from the Foundation of the NIH AML MRD Biomarkers Consortium. Fabio Efficace had a consultancy or advisory role for Amgen, AbbVie, Janssen, and Novartis and received research funding (institutional) from AbbVie, Amgen and Novartis; outside the submitted work. Pierre Fenaux received research funding from BMS, Abbvie, Jazz Pharmaceuticals, Novartis, and Janssen. Pierre Fenaux had a consultancy with and received honoraria from BMS, Abbvie, Jazz Pharmaceuticals, and Novartis. Maximilian Stahl consulted for Curis Oncology and Boston Consulting; served on the advisory board for Novartis and Kymera; and participated in GME activity for Novartis, Curis Oncology, Haymarket Media and Clinical care options (CCO). GS received grants/research supports (institutional) from BMS, Novartis, and Gamida Cell. RM is on the Board of Directors of CircBio, the Advisory Boards of Kodikaz Therapeutic Solutions, Syros Pharmaceuticals, and TenSixteen Bio, and is an inventor on a number of patents related to CD47 cancer immunotherapy licensed to Gilead Sciences. RM receives research support from Gilead Sciences and CircBio. RM is a co-founder and equity holder of CircBio, Pheast Therapeutics, MyeloGene, and RNAC Therapeutics. GS received honoraria, advisory board membership or consultation fees from AbbVie, BMS, Novartis, Roche, and Takeda and participated in sponsored speaker’s bureau for BMS, Novartis, and Takeda. AN owns stock at Amazon and is an employee of Incyte Pharmaceuticals. Olatoyosi Odenike has served on the advisory board of Bristol-Myers Squibb, Celgene, Novartis, Taiho and Kymera Therapeutics; serves on a DSMB for Threadwell Therapeutics and received research funding (institutional) from ABBVIE, Agios, aprea, Astex, Astra Zeneca, Bristol Myers Squibb, Celgene, CTI, Daiichi, Incyte, Janssen, Kartos, Novartis, NS-Pharma and Oncotherapy Sciences. DTS is a consultant and received research funding from Kymera Therapeutics, Kurome Therapeutics, Captor Therapeutics, and Tolero Therapeutics. DTS has equity in Kurome Therapeutics. DAS served on the advisory board of Aprea, AvenCell, BlueBird Bio, BMS, Intellia, Kite, Novartis, Shattuck Labs, Servier, Syndax. DAS served as a consultant for AbbVie, Magenta, Molecular Partners AG, Takeda and on the speakers’ bureau for BMS, Incyte, Servier; DAS received research funding from Aprea, Jazz. Mrinal Patnaik received research funding from Kura Oncology and StemLine Pharmaceuticals. AB received consulting or advisory board honoraria from Novartis, Acceleron, Agios, Abbvie, Takeda, Celgene/BMS, Keros Therapeutics, Taiho, Gilead. AB has research support from the NIH SPORE in Myeloid Malignancies, and from the Edward P. Evans Foundation. EP receives research funding from Incyte and BMS and honoraria from stemline, Taiho, Blueprint, and BMS. TKK received research funding from Nextcure and is a consultant for Agenus. RSK served on the speaker bureau of JAZZ, Servio, CTI, pharmaEssentia. RSK served on advisory boards and received honoraria from BMS, Novartis, Abbvie, JAZZ, servio, pharmaEssentia, Taiho, Geron, CTI. MAS has served on advisory boards for BMS, Novartis, Kurome, and Gilead. RB is employed by and has equity in Aptose Biosciences. RB serves on independent drug monitoring committees for Gilead and Epizyme. RPH has a consultancy with Bluebird Bio. Gail J. Roboz has a consultancy and/or serves on the advisory Board or Data and Safety Monitoring Committee for AbbVie, Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Blueprint Medicines, Bluebird Bio, Celgene, Glaxo SmithKline, Janssen, Jasper Therapeutics, Jazz, Mesoblast, Novartis, Pfizer, Syndax, Takeda. GR received research support from Janssen. Stephanie Halene received honoraria from FORMA Therapeutics. Andrew H.Wei has served on advisory boards for Novartis, Astra Zeneca, Astellas, Janssen, Amgen, Roche, Pfizer, Abbvie, Servier, Gilead, BMS, Shoreline, Macrogenics and Agios; receives research funding to the Institution from Novartis, Abbvie, Servier, Janssen, BMS, Syndax, Astex, Astra Zeneca, Amgen; serves on speaker’s bureaus for Abbvie, Novartis, BMS, Servier, Astellas; Andrew H.Wei is an employee of the Walter and Eliza Hall Institute (WEHI) and is eligible for financial benefits associated with payments which WEHI receives in relation to venetoclax. Alan List is employed by and has equity in Precision BioSciences, and has served as a consultant for Halia Therapeutics, CTI Biopharma, Aileron. Mina Xu participated in advisory boards and/or had a consultancy with and received honoraria from Seattle Genetics, Pure Marrow and Blueprint Medicines. ND has received research funding from Daiichi-Sankyo, Bristol-Myers Squibb, Pfizer, Gilead, Sevier, Genentech, Astellas, Daiichi-Sankyo, Abbvie, Hanmi, Trovagene, FATE therapeutics, Amgen, Novimmune, Glycomimetics, Trillium, and ImmunoGen and has served in a consulting or advisory role for Daiichi-Sankyo, Bristol-Myers Squibb, Arog, Pfizer, Novartis, Jazz, Celgene, AbbVie, Astellas, Genentech, Immunogen, Servier, Syndax, Trillium, Gilead, Amgen, Shattuck labs, and Agios. SL received research support from Astellas, Amgen; owns stock from Abbvie, and has received consultancy fees/honoraria from Abbvie, Gerson Lehrman Group, QualWorld, Guidepoint. EAG received honoraria from Abbvie, Alexion Pharmaceuticals, Genentech, Novartis, CTI biopharma, Apellis, Celgene/BMS, Takeda Oncology, Taiho Oncology, Physician Educational Resource, MediCom Worldwide, American Society of Hematology, Picnic Health, AAMDSIF and research support (institutional) from Astex Pharmaceuticals, Genentech, Blueprint Medicine, Alexion Pharmaceuticals, Apellis, BMS/Celgene, Celldex Therapeutics. MS serves on a Board or Advisory Committee for Abbvie, Bristol Myers Squibb, CTI, Forma, Geron, Karyopharm, Novartis, Ryvu, Sierra Oncology, Taiho, Takeda, TG Therapeutics, receives research funding from ALX Oncology, Astex, Incyte, Takeda, TG Therapeutics; and has equity ownership: Karyopharm, Ryvu. OA-W has served as a consultant for H3B Biomedicine, Foundation Medicine Inc, Merck, Prelude Therapeutics, and Janssen, and is on the Scientific Advisory Board of Envisagenics Inc., AIChemy, Harmonic Discovery Inc., and Pfizer Boulder; OA-W has received prior research funding from H3B Biomedicine and LOXO Oncology unrelated to the current manuscript. All other authors have no conflicts of interest to disclose.
